Lexicon Pharmaceuticals, Inc.
LXRXFigures shown here come from public SEC filings. Dates beside each section show the available history.
How Lexicon Pharmaceuticals, Inc. Makes Money
Follow each dollar of revenue through to what shareholders keep.
From revenue to net income
Pick a year or quarter. Each band's width is its dollar amount.
Financial Summary
Choose a year or quarter, compare it with the same period a year earlier, and open any row for its full filing history.
Loading financial history…
SEC filings supply these figures; updates after the dates shown are not included. This page includes 5 annual periods. The latest annual period ends Dec 31, 2025. The latest insider filing shown is dated Jun 4, 2026.
Ownership
Who holds the shares, as reported in SEC ownership filings.
Purchases & sales (open market or private)
| Security | Code | Price | Filing | |||
|---|---|---|---|---|---|---|
| 2026-02-25 | DEBBANE RAYMOND · Director | Common Stock | P — Open market or private purchase | +2,000 | 1.49 | SEC filing |
| 2026-02-23 | DEBBANE RAYMOND · Director | Common Stock | P — Open market or private purchase | +100,000 | 1.47 | SEC filing |
| 2026-02-20 | DEBBANE RAYMOND · Director | Common Stock | P — Open market or private purchase | +100,000 | 1.48 | SEC filing |
| 2026-02-19 | DEBBANE RAYMOND · Director | Common Stock | P — Open market or private purchase | +50,000 | 1.44 | SEC filing |
| 2026-02-18 | DEBBANE RAYMOND · Director | Common Stock | P — Open market or private purchase | +133,688 | 1.32 | SEC filing |
| 2026-02-17 | DEBBANE RAYMOND · Director | Common Stock | P — Open market or private purchase | +76,857 | 1.31 | SEC filing |
| 2026-02-13 | DEBBANE RAYMOND · Director | Common Stock | P — Open market or private purchase | +57,952 | 1.31 | SEC filing |
| 2026-02-02 | DEBBANE RAYMOND · Director | Common Stock | P — Open market or private purchase | +1,538,462 | 1.30 | SEC filing |
Showing 8 of 8 rows
Grants, exercises, tax & gifts
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2026-06-03 | BARKER SAM L · Director | Common Stock | M — Exercise or conversion of derivative security | +89,312 | SEC filing |
| 2026-06-03 | SOBECKI CHRISTOPHER J · Director | Restricted Stock Units | M — Exercise or conversion of derivative security | −89,312 | SEC filing |
| 2026-06-03 | Cheung Ivan · Director | Restricted Stock Units | M — Exercise or conversion of derivative security | −89,312 | SEC filing |
| 2026-06-03 | Cheung Ivan · Director | Common Stock | M — Exercise or conversion of derivative security | +89,312 | SEC filing |
| 2026-06-03 | Amouyal Philippe · Director | Common Stock | M — Exercise or conversion of derivative security | +89,312 | SEC filing |
| 2026-06-03 | BARKER SAM L · Director | Restricted Stock Units | M — Exercise or conversion of derivative security | −89,312 | SEC filing |
| 2026-06-03 | SOBECKI CHRISTOPHER J · Director | Common Stock | M — Exercise or conversion of derivative security | +89,312 | SEC filing |
| 2026-06-03 | Swain Judith L · Director | Restricted Stock Units | M — Exercise or conversion of derivative security | −89,312 | SEC filing |
Showing 8 of 30 rows
These tables describe filed transactions, not current holdings. Prices are shown as filed; a currency is added only when the filing's data names one. Amended and possible duplicate rows are left out of size comparisons and transaction groups.